Please login to the form below

Not currently logged in
Email:
Password:

Shire makes strong start to 2011

Shire reports rise in operating profit and sales in the first half of 2011

Shire has posted a 22 per cent increase in first-quarter operating income, under Generally Accepted Accounting Principles, to $267m.

The company reported that total revenues for the period were up by 19 per cent to $972m in Q1, but increased sales were partially offset by lower royalties, due to lower royalty income from Impax Laboratories' authorised generic version of ADDERALL XR.

The company said: "For the full year 2011 we continue to expect good product sales growth, in line with the growth rate achieved in 2010, driven by our young product portfolio, offsetting the impact of the sale of DAYTRANA last year. We expect total royalty and other revenues to be down 10 per cent compared to 2010. Gross margins we anticipate being at a similar percentage of product sales for the full year 2011 as seen in the first quarter."

It said that it has identified opportunities for future growth both by advancing its pipeline and continuing the international expansion.

28th April 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To transform lives through communication that changes behaviour and improves health outcomes....

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...